|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04010399
|
4-A4-NeuroP
|
(S,E)-4-hydroxy-6-((1R,5R)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010463
|
4-J4-NeuroP
|
(S,E)-4-hydroxy-6-((1S,5S)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010425
|
4-epi-11-A4-NeuroP
|
3-((1S,2R)-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010489
|
4-epi-11-J4-NeuroP
|
3-((1R,5S)-5-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010395
|
4-epi-4-A4-NeuroP
|
(R,E)-4-hydroxy-6-((1R,5R)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010459
|
4-epi-4-J4-NeuroP
|
(R,E)-4-hydroxy-6-((1S,5S)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010405
|
7,10-diepi-7-A4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,2R)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010469
|
7,10-diepi-7-J4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,5S)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010437
|
7,14-diepi-14-A4-NeuroP
|
(Z)-6-((1S,2R)-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010501
|
7,14-diepi-14-J4-NeuroP
|
(Z)-6-((1R,5S)-5-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010407
|
7-A4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1R,2R)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010471
|
7-J4-NeuroP
|
(S,4Z,8E)-7-hydroxy-9-((1S,5S)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010441
|
7-epi-14-A4-NeuroP
|
(Z)-6-((1S,2R)-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010505
|
7-epi-14-J4-NeuroP
|
(Z)-6-((1R,5S)-5-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010401
|
7-epi-4-A4-NeuroP
|
(S,E)-4-hydroxy-6-((1S,5R)-2-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-3-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010465
|
7-epi-4-J4-NeuroP
|
(S,E)-4-hydroxy-6-((1R,5S)-4-oxo-5-((2Z,5Z,8Z)-undeca-2,5,8-trien-1-yl)cyclopent-2-en-1-yl)hex-5-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010403
|
7-epi-7-A4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2R)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010467
|
7-epi-7-J4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,5S)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010416
|
ent-10,13-diepi-10-A4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,5S)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010480
|
ent-10,13-diepi-10-J4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,5R)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010448
|
ent-10,17-diepi-17-A4-NeuroP
|
(4Z,7Z)-9-((1R,2S)-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010512
|
ent-10,17-diepi-17-J4-NeuroP
|
(4Z,7Z)-9-((1S,5R)-5-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010414
|
ent-10-A4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,5S)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010478
|
ent-10-J4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,5R)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010418
|
ent-10-epi-10-A4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1S,5S)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010482
|
ent-10-epi-10-J4-NeuroP
|
(S,4Z,7Z,11E)-10-hydroxy-12-((1R,5R)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010444
|
ent-10-epi-17-A4-NeuroP
|
(4Z,7Z)-9-((1R,2S)-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010508
|
ent-10-epi-17-J4-NeuroP
|
(4Z,7Z)-9-((1S,5R)-5-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010404
|
ent-10-epi-7-A4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1R,2S)-2-((2Z,5Z)-octa-2,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010468
|
ent-10-epi-7-J4-NeuroP
|
(R,4Z,8E)-7-hydroxy-9-((1S,5R)-5-((2Z,5Z)-octa-2,5-dien-1-yl)-4-oxocyclopent-2-en-1-yl)nona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010422
|
ent-11-A4-NeuroP
|
3-((1S,2S)-2-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010486
|
ent-11-J4-NeuroP
|
3-((1R,5R)-5-((R,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010426
|
ent-11-epi-11-A4-NeuroP
|
3-((1S,2S)-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-5-oxocyclopent-3-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010490
|
ent-11-epi-11-J4-NeuroP
|
3-((1R,5R)-5-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)-4-oxocyclopent-2-en-1-yl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010432
|
ent-13,16-diepi-13-A4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2S)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010496
|
ent-13,16-diepi-13-J4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,5R)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010456
|
ent-13,20-diepi-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S)-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010520
|
ent-13,20-diepi-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,5R)-5-((S,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010430
|
ent-13-A4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2S)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010494
|
ent-13-J4-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,5R)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010412
|
ent-13-epi-10-A4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1R,5S)-2-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-3-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010476
|
ent-13-epi-10-J4-NeuroP
|
(R,4Z,7Z,11E)-10-hydroxy-12-((1S,5R)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010434
|
ent-13-epi-13-A4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2S)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010498
|
ent-13-epi-13-J4-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,5R)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010452
|
ent-13-epi-20-A4-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S)-2-((R,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010516
|
ent-13-epi-20-J4-NeuroP
|
(4Z,7Z,10Z)-12-((1S,5R)-5-((R,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010438
|
ent-14-A4-NeuroP
|
(Z)-6-((1S,2S)-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010502
|
ent-14-J4-NeuroP
|
(Z)-6-((1R,5R)-5-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010442
|
ent-14-epi-14-A4-NeuroP
|
(Z)-6-((1S,2S)-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|
|
LMFA04010506
|
ent-14-epi-14-J4-NeuroP
|
(Z)-6-((1R,5R)-5-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
358.21
|
C22H30O4
|